Long-term survival analysis of masitinib in amyotrophic lateral sclerosis.

Jesus S MoraWalter G BradleyDelia ChaverriMaría Hernández-BarralJavier MasciasJosep GamezGisella M Gargiulo-MonachelliAlain MoussyColin D MansfieldOlivier HermineAlbert C Ludolph

Published in: Therapeutic advances in neurological disorders (2021)

Analysis of long-term OS (75 months average follow-up from diagnosis) indicates that oral masitinib (4.5 mg/kg/day) could prolong survival by over 2 years as compared with placebo, provided that treatment starts prior to severe impairment of functionality.This trial was registered at www.ClinicalTrials.gov under identifier NCT02588677 (28 October 2015).

Keyphrases

phase iii
clinical trial
study protocol
early onset
phase ii
randomized controlled trial
double blind
free survival
open label